Shipments of the affected viable bone matrix material were sent to seven states between Feb. 27 and June 20, the CDC said July 25. Aziyo Biologics, which manufactured the material, voluntarily recalled its viable bone matrix products July 13. Infections stemmed from a single lot that initially tested negative for Mycobacterium tuberculosis before it was released.
At least 36 patients were treated with the products, the CDC told Becker’s. Forty-three units of ViBone were shipped along with seven units of alloOss, a dental implant.
The CDC and FDA are working with state and local health officials to prevent further patient harm. The agency is advising hospitals and dental offices to notify any personnel who may have been exposed during patient care.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
